The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Angiotensin II receptor antagonist treatment during pregnancy
Open accessAbstract
Angiotensin II (A‐II) is the main effector of the renin‐angiotensin system. A‐II functions by binding its type 1 (AT1) receptors to cause vasoconstriction and retention of sodium and fluid. Several AT1 receptor antagonists—a group of drugs collectively called “sartans”—have been marketed during the past few years for treatment of hypertension and heart failure. At least 15 case reports describe oligohydramnios, fetal growth retardation, pulmonary hypoplasia, limb contractures, and calvarial hypoplasia in various combinations in association with maternal losartan, candesartan, valsartan, or telmisartan treatment during the second or third trimester of pregnancy. Stillbirth or neonatal death is frequent in these reports, and surviving infants may exhibit renal damage. The fetal abnormalities, which are strikingly similar to those produced by maternal treatment with angiotensin‐converting enzyme (ACE) inhibitors during the second and third trimesters of pregnancy, are probably related to extreme sensitivity of the fetus to the hypotensive action of these drugs. Very little information is available regarding the outcome of human pregnancies in which the mother was treated with an AT1 receptor antagonist during the first trimester, but animal studies have not demonstrated teratogenic effects after maternal treatment with large doses of AT1 receptor antagonists during organogenesis. We conclude that pharmacological suppression of the fetal renin‐angiotensin system through ACE inhibition or AT1 receptor blockade seems to disrupt fetal vascular perfusion and renal function. We recommend that maternal treatment with AT1 receptor antagonists be avoided during the second and third trimesters of pregnancy and that women who become pregnant while taking one of these medications be changed to an antihypertensive drug of a different class as soon as the pregnancy is recognized. Birth Defects Research (Part A) 73, 2004. © 2004 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfeffer, M. A., Braunwald, E., Moyé, L. A., Basta, L., Brown, E. J., Cuddy, T. E., Davis, B. R., Geltman, E. M., Goldman, S., Flaker, G. C., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199209033271001 · Cited by 5,911
Shotan, A., Widerhorn, J., Hurst, A., & Elkayam, U. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90172-4 · Cited by 300
Cited by
Evolving knowledge of the teratogenicity of medications in human pregnancy
Adam, M. P., Polifka, J. E., & Friedman, J. M. (2011) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30313 · Cited by 376
Self-citationBullo, M., Tschumi, S., Bucher, B. S., Bianchetti, M. G., & Simonetti, G. D. (2012) · Hypertension · doi:10.1161/hypertensionaha.112.196352 · Cited by 334
Quan, A. (2006) · Early Human Development · doi:10.1016/j.earlhumdev.2005.11.001 · Cited by 200
Phytochrome Kinase Substrate 4 is phosphorylated by the phototropin 1 photoreceptor
Demarsy, E., Schepens, I., Okajima, K., Hersch, M., Bergmann, S., Christie, J., Shimazaki, K., Tokutomi, S., & Fankhauser, C. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.186 · Cited by 94
Bone Homeostasis: An Emerging Role for the Renin-Angiotensin System
Sernia, C., Huang, H., Nguyuen, K., Li, Y.-H., Hsu, S., Chen, M., Yu, N., & Forwood, M. (2007) · Frontiers in Research of the Renin-Angiotensin System on Human Disease · doi:10.1007/978-1-4020-6372-5_9 · Cited by 4
Metadata
- Authors
- Alwan, S., Polifka, J. E., & Friedman, J. M.
- Venue
- Birth Defects Research Part A: Clinical and Molecular Teratology
- Publisher
- Wiley
- Published
- 2005-01-24
- Volume
- 73
- Issue
- 2
- Pages
- 123-130
- ISSN
- 1542-0752 (ISSN-L)
- 1542-0760
- OpenAlex
- W2045675189
- Cited by
- 247
- References
- 2
- FWCI
- 15.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.